Conor E. Steuer, MD

One star
One star
One star
One star
One half star

Rating: 4.8 out of 5 (156 ratings)

Role

Medical Oncology
Specialty

Esophageal Cancer Head and Neck Cancer Lung Cancer Thymoma and Thymic Cancer Thyroid Cancer
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2015

Call 404-778-1900

Background

Conor E. Steuer, MD, is a board certified medical oncologist specializing in the care of aerodigestive cancers, mesothelioma and thymic malignancies. He joined the clinical staff at Winship Cancer Institute as a practicing physician in 2015.

Dr. Steuer is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He currently serves as chair of the Lung and Aerodigestive Malignancies Working Group.

Dr. Steuer received his medical degree from NYU School of Medicine. He completed his postdoctoral training as a Fellow in the Department of Hematology and Medical Oncology at Emory University School of Medicine where he was Chief Fellow in his final year.

Titles & Roles

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Education & Training

Education

Fellowship, Hematology & Oncology, 2015
Emory University School of Medicine
Residency, Internal Medicine, 2012
Emory University School of Medicine
Medical Education, MD, 2009
New York University

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2015
Hematology
American Board of Internal Medicine, 2015
Internal Medicine
American Board of Internal Medicine, 2012

Research

Dr. Steuer has been active in research including clinical trial development, database analyses, and investigation of molecular biomarkers. He is interested in investigating the molecular biology and genomics of thoracic and head and neck tumors in order to be able to further the care of these patient populations. Additionally, he has taken an interest in utilizing national databases to perform clinical outcomes research, as well as further investigate rare forms of thoracic cancers.

View Current Clinical Trials


Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Phase II Conditions Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Location Emory University Hospital Midtown, Winship Cancer Institute
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer Phase II Conditions Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers Phase II Conditions Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma Location Emory University Hospital Midtown
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Phase II Conditions Salivary Gland Cancer, HER2 Gene Mutation Location Emory University Hospital Midtown
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer Phase I Conditions Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8 Location Emory University Hospital Midtown, Winship Cancer Institute
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Phase I Conditions Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma Location Emory University Hospital Midtown, Winship Cancer Institute

Publications

Dr. Steuer's work has been published in many leading journals, such as Cancer, Journal of Thoracic Oncology, and Lung Cancer, as well as presented at multiple international conferences.

Title/Journal	Authors	Publication Date
Colocated Multidisciplinary Clinic Is Associated With Improved Timeliness to Postoperative Adjuvant Therapy in Head and Neck Cancer Patients Head & Neck	GE Daoud, MF Riedel, MJ Ryan, M Gaonkar, MP Mehta, KT Hendler, WA Stokes, JE Bates, J Remick, DM Shin, CE Steuer, NF Saba, MW El-Deiry, PW Kahng, JH Gross, HM Baddour, NC Schmitt, AS Kaka, MR Patel, BJ Boyce, S Rudra	04/06/2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950). Cancer	A Bhatia, Z Chen, Y Zhang, JY Bruce, S Arnold, V Kaur, JW Riess, M Fenton, B Burtness, NF Saba, H Tara, CE Steuer, DM Shin, G Wasp, TH Davis, M Patel, JC Schmitz, P Bhateja, V Diavolitsis, DP Zandberg, DL Mitchell, BF Kiesel, C Kunos, SD Gore, M Carducci, JH Beumer, TK Owonikoko	03/15/2026
Minimizing Chemoradiation Using a Surgical Algorithm for HPV‐Associated Cancer of Unknown Primary Head & Neck	GE Daoud, AJ Burnham, NT Vettikattu, NC Schmitt, BJ Boyce, JH Gross, HM Baddour, MW El-Deiry, CE Steuer, NF Saba, JE Bates, WA Stokes, KR Magliocca, MR Patel, AS Kaka	12/08/2025
Survival Determinants and Sociodemographic Disparities in Early-Onset Non–Small Cell Lung Cancer JAMA Network Open	I Kar, F Vhora, M Bou Zerdan, K Canaslan, D Balaji, B El Osta, S Balaji, K O'Reilly, T Leal, T Jain, S Ramalingam, CE Steuer, JW Carlisle, S Bozkurt, F Ardeshir-Larijani	10/13/2025
Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cancer The Oncologist	OB Alese, RD Harvey, C Wu, E Hitron, H Collins, S Scott, C Steuer, MA Bilen, BC Carthon, JM Switchenko, SS Ramalingam, TK Owonikoko	09/17/2025
Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial American Journal of Clinical Oncology	R Park, F Rind, T Kristoff, J Li, M Schell, RJC Slebos, S Thatikonda, R Chaudhary, MI Biernacki, Y Meshkovska, D Kaldas, HS Kim, J Farinhas, J Hernandez-Prera, K Kirtane, MS Hall, AL Amelio, JW Rocco, P Bhateja, C Steuer, M Bonomi, NF Saba, CH Chung	09/04/2025
Radiotherapy With Cisplatin vs Carboplatin Paclitaxel for Head and Neck Squamous Cell Carcinoma JAMA Otolaryngology–Head & Neck Surgery	M Abousaud, S Pamulapati, S Rashid, F Lozano, M Shepherd, B Fowowe, Y Cao, P Kim, Y Liu, JE Bates, JE Bates, M McDonald, S Rudra, WA Stokes, WA Stokes, J Gross, NC Schmitt, MW El-Deiry, MR Patel, AL Hammond, Y Teng, C Steuer, DM Shin, NF Saba	06/26/2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy Journal of Clinical Oncology	CE Steuer, H Hayashi, WC Su, M Nishio, ML Johnson, DW Kim, E Massarelli, E Felip, KA Gold, H Murakami, CS Baik, SW Kim, EF Smit, M Fujimura, PD Fan, K Truchon, X Su, DW Sternberg, PA Jänne	06/24/2025
Reirradiation: Standards, challenges, and patient‐focused strategies across tumor types CA A Cancer Journal for Clinicians	A Beddok, J Willmann, A Embring, AL Appelt, P Balermpas, K Chua, JI Choi, BS Elger, D Gabrys, P Hoskin, M Niyazi, D Pasquier, K Paradis, O Kaidar-Person, C Plaisier, NC Schmitt, CE Steuer, J Thariat, SS Yom, P Poortmans, E Vasquez Osorio, N Andratschke	05/29/2025
Early-Phase Trial of IAP Antagonist Tolinapant and Definitive Radiation in Cisplatin-Ineligible Patients with Advanced Head and Neck Cancer Clinical Cancer Research	NC Schmitt, WA Stokes, JE Bates, BLC Kinney, J Remick, MW McDonald, S Rudra, M Steininger, M Oyewole, MR Patel, AS Kaka, JH Gross, J Switchenko, CE Steuer, DM Shin, NF Saba	05/12/2025
Statin Drugs Are Associated With Response to Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer Cancer Medicine	TJ Kristoff, S Evans, P Nayi, M Abousaud, S Goyal, Y Liu, D Shin, CE Steuer, NF Saba, NC Schmitt	03/01/2025
Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies Cancers	E Xue, D Bracken-Clarke, H Krause, T Adeyelu, MG Evans, D Akbulut, M Quezado, N Gandhi, A Farrell, HP Soares, E Lou, M Phan, R Patel, AM Vanderwalde, A Elliott, CE Steuer, NF Saba, DJ Lubin, NR London, JL Gulley, CS Floudas	11/24/2024
Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis Clinical Cancer Research	NF Saba, R Chaudhary, K Kirtane, A Marra, A Ekpenyong, A McCook-Veal, NC Schmitt, JH Gross, MR Patel, J Remick, JE Bates, MW McDonald, SF Rudra, WA Stokes, M Biernacki, X Song, RJC Slebos, Y Liu, CE Steuer, DM Shin, Y Teng, CH Chung	08/21/2024
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations The Lancet Oncology	AM Lim, C Le Tourneau, C Hurt, SG Laskar, CE Steuer, VLY Chow, P Szturz, C Henson, AT Day, JE Bates, S Lazarakis, L McDowell, H Mehanna, SS Yom	06/24/2024
Institution-level Patterns of Care for Early-stage Oropharynx Cancers in the United States American Journal of Clinical Oncology	JR Janopaul-Naylor, Y Liu, Y Cao, AJ Schlafstein, C Steuer, MR Patel, JE Bates, MW McDonald, WA Stokes	06/20/2024
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma JAMA Oncology	NF Saba, SJ Wong, T Nasti, AA McCook-Veal, MW McDonald, WA Stokes, AM Anderson, A Ekpenyong, M Rupji, M Abousaud, S Rudra, JE Bates, JS Remick, NP Joshi, NM Woody, M Awan, JL Geiger, A Shreenivas, J Samsa, MC Ward, NC Schmitt, MR Patel, KA Higgins, Y Teng, CE Steuer, DM Shin, Y Liu, R Ahmed, SA Koyfman	05/23/2024
Assessing survival outcomes of patients with oral tongue squamous cell carcinoma: Focus on age, sex, and stage Head & Neck	S Pamulapati, M Abousaud, Y Li, A Ekpenyong, S Rudra, JS Remick, JE Bates, WA Stokes, MW McDonald, NC Schmitt, MW El-Deiry, MR Patel, CE Steuer, JM Switchenko, DM Shin, Y Teng, A Hammond, NF Saba	05/02/2024
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI Future Oncology	T Mok, PA Jänne, M Nishio, S Novello, M Reck, C Steuer, YL Wu, R Fougeray, PD Fan, J Meng, DW Sternberg, S Esker, HA Yu	12/14/2023
Critical review of the current and future prospects of VEGF-TKIs in the management of squamous cell carcinoma of head and neck Frontiers in Oncology	P Puttagunta, SV Pamulapati, JE Bates, JH Gross, WA Stokes, NC Schmitt, C Steuer, Y Teng, NF Saba	12/13/2023
The evolving landscape of salivary gland tumors CA A Cancer Journal for Clinicians	CE Steuer, GJ Hanna, K Viswanathan, JE Bates, AS Kaka, NC Schmitt, AL Ho, NF Saba	07/25/2023
Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement The Laryngoscope	RJ So, JC Hidalgo Lopez, SA Ballestas, AM Klein, C Steuer, DM Shin, M Abousaud, Y Teng, NF Saba, AT Tkaczuk, ES Schaefer, TY Seiwert, K McClellan, SR Best	07/20/2023
Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non–small cell lung cancer Cancer	NS McCall, JR Janopaul-Naylor, HS McGinnis, AH Kesarwala, S Tian, WA Stokes, JW Shelton, CE Steuer, JW Carlisle, TA Leal, SS Ramalingam, JD Bradley, KA Higgins	06/24/2023
Patient‐reported outcomes in immunotherapy for head and neck cancer Head & Neck	K Kirtane, AI Hoogland, X Li, Y Rodriguez, K Scheel, BJ Small, LB Oswald, J Muzaffar, JA Kish, M Bonomi, P Bhateja, NF Saba, CE Steuer, CH Chung, HSL Jim	05/04/2023
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial Nature Medicine	NF Saba, CE Steuer, A Ekpenyong, A McCook-Veal, K Magliocca, M Patel, NC Schmitt, W Stokes, JE Bates, S Rudra, J Remick, M McDonald, M Abousaud, AC Tan, MZH Fadlullah, R Chaudhary, J Muzaffar, K Kirtane, Y Liu, GZ Chen, DM Shin, Y Teng, CH Chung	04/01/2023
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial Clinical Cancer Research	DS Hong, M Postow, B Chmielowski, R Sullivan, A Patnaik, EEW Cohen, G Shapiro, C Steuer, M Gutierrez, H Yeckes-Rodin, R Ilaria, B O'Connell, J Peng, G Peng, N Zizlsperger, A Tolcher, JD Wolchok	03/31/2023
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer Journal of Clinical Oncology	JE Bauman, NF Saba, D Roe, JR Bauman, J Kaczmar, A Bhatia, J Muzaffar, R Julian, S Wang, S Bearelly, A Baker, C Steuer, A Giri, B Burtness, S Centuori, C Caulin, R Klein, K Saboda, S Obara, CH Chung	03/28/2023
Long‐Term Follow‐up of Parenteral Bevacizumab In Patients with Recurrent Respiratory Papillomatosis The Laryngoscope	SA Ballestas, J Hidalgo Lopez, AM Klein, C Steuer, DM Shin, M Abousaud, NC Schmitt, Y Teng, NF Saba, AT Tkaczuk	02/23/2023
Ninety‐day mortality following transoral robotic surgery or radiation at Commission on Cancer‐accredited facilities Head & Neck	JR Janopaul-Naylor, M Rupji, RA Tobillo, JW Lorenz, JM Switchenko, S Tian, AS Kaka, DC Qian, AJ Schlafstein, CE Steuer, JS Remick, S Rudra, MW McDonald, NF Saba, WA Stokes, MR Patel, JE Bates	12/22/2022
Specimen-Based Resection Margins and Local Control during Transoral Robotic Surgery for Oropharyngeal HPV-Mediated Squamous Cell Carcinoma ORL	KR Magliocca, AS Kaka, EM Barrow, MB Studer, CC Griffith, J Ernst, T Meade, A Balicki, BJ Boyce, NC Schmitt, AM Bur, AC Schmitt, R Jackson, CE Steuer, JJ Beitler, MR Patel	12/20/2022
Immune check point inhibitors in advanced cutaneous squamous cell carcinomas: “Repeat and replicate” Cancer	CE Steuer, NF Saba	10/24/2022
Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era Radiotherapy and Oncology	NS McCall, HS McGinnis, JR Janopaul-Naylor, AH Kesarwala, S Tian, WA Stokes, JW Shelton, CE Steuer, JW Carlisle, T Leal, SS Ramalingam, JD Bradley, KA Higgins	07/20/2022
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant Journal of Clinical Oncology	RM Valanparambil, J Carlisle, SL Linderman, A Akthar, RL Millett, L Lai, A Chang, AA McCook-Veal, J Switchenko, TH Nasti, M Saini, A Wieland, KE Manning, M Ellis, KM Moore, SL Foster, K Floyd, ME Davis-Gardner, VV Edara, M Patel, C Steur, AK Nooka, F Green, MA Johns, F O'Brein, U Shanmugasundaram, VI Zarnitsyna, H Ahmed, H Ahmed, LE Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, MS Suthar, MV Dhodapkar, S Ramalingam, R Ahmed	06/27/2022
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non–Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade Clinical Lung Cancer	BE Osta, J Carlisle, C Steuer, S Pakkala, T Leal, M Dhodapkar, Y Liu, Z Chen, T Owonikoko, S Ramalingam	06/22/2022
T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma Journal for ImmunoTherapy of Cancer	X Wang, J Muzaffar, K Kirtane, F Song, M Johnson, MJ Schell, J Li, SJ Yoder, JR Conejo-Garcia, JA Guevara-Patino, M Bonomi, P Bhateja, JW Rocco, CE Steuer, NF Saba, CH Chung	06/01/2022
A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer Cancers	JE Bauman, Z Chen, C Zhang, JP Ohr, RL Ferris, GM McGorisk, S Brandt, S Srivatsa, AY Chen, CE Steuer, DM Shin, NF Saba, FR Khuri, TK Owonikoko	05/26/2022
Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab Oral Oncology	DJ Glazar, M Johnson, J Farinhas, CE Steuer, NF Saba, M Bonomi, CH Chung, H Enderling	03/04/2022
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Clinical Cancer Research	CH Chung, J Li, CE Steuer, P Bhateja, M Johnson, J Masannat, MI Poole, F Song, JC Hernandez-Prera, H Molina, BM Wenig, S Kumar, C Kuperwasser, PJ Stephens, JM Farinhas, DM Shin, JA Kish, J Muzaffar, K Kirtane, JW Rocco, MJ Schell, NF Saba, M Bonomi	03/01/2022
HPV as a Carcinomic Driver in Head and Neck Cancer: a De-escalated Future? Current Treatment Options in Oncology	JE Bates, CE Steuer	03/01/2022
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern medRxiv	R Valanparambil, J Carlisle, S Linderman, A Akthar, RL Millett, L Lai, A Chang, A McCook, J Switchenko, T Nasti, M Saini, AW Andreas Wieland, K Manning, M Ellis, K Moore, S Foster, K Floyd, M Davis-Gardner, V Viswanadh Edara, M Patel, C Steur, A Nooka, F Green, M Johns, F O Brein, U Shanmugasundaram, V Zarnitsyna, H Ahmed, H Ahmed, L Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, M Suthar, M Dhodapkar, S Ramalingam, R Ahmed	01/03/2022
Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas The Oncologist	P Vijayvargiya, S Trivedi, M Rupji, H Song, Y Liu, R Jiang, AS Kaka, GZ Chen, W Stokes, C Steuer, DM Shin, JJ Beitler, MR Patel, A Aiken, NF Saba	01/01/2022
The omission of intentional primary site radiation following transoral robotic surgery in 59 patients: No local‐regional failures Head & Neck	VR Dhere, CE Escott, S Tian, JM Switchenko, JP Bell, WA Stokes, MW McDonald, KR Magliocca, BJ Boyce, AS Kaka, CE Steuer, NF Saba, DM Shin, C Xiao, MR Patel, JJ Beitler	12/01/2021
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer Cancer Discovery	PA Jänne, C Baik, WC Su, ML Johnson, H Hayashi, M Nishio, DW Kim, M Koczywas, KA Gold, CE Steuer, H Murakami, JC Yang, SW Kim, M Vigliotti, R Shi, Z Qi, Y Qiu, L Zhao, D Sternberg, C Yu, HA Yu	09/21/2021
Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population––A SEER‐based analysis from 2000 to 2016 Cancer Medicine	MA Taylor, J Switchenko, W Stokes, MR Patel, M McDonald, C Steuer, A Aiken, JJ Beitler, DM Shin, NF Saba	07/20/2021
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors The Oncologist	KT Do, LQM Chow, K Reckamp, RE Sanborn, H Burris, F Robert, DR Camidge, CE Steuer, JH Strickler, A Weise, JM Specht, M Gutierrez, P Haughney, S Hengel, CL Derleth, TA Yap	07/20/2021
Advances in Immunotherapy and Implications for Current Practice in Non–Small-Cell Lung Cancer JCO Oncology Practice	CE Steuer, SS Ramalingam	06/25/2021
Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus Radiotherapy and Oncology	F Carsuzaa, M Lapeyre, V Gregoire, P Maingon, A Beddok, PY Marcy, J Salleron, A Coutte, S Racadot, Y Pointreau, P Graff, B Beadle, K Benezery, J Biau, V Calugaru, J Castelli, M Chua, A Di Rito, M Dore, P Ghadjar, F Huguet, P Jardel, J Johansen, R Kimple, M Krengli, S Laskar, L Mcdowell, A Nichols, S Tribius, I Valduvieco, C Hu, X Liem, A Moya-Plana, I D'onofrio, U Parvathaneni, V Takiar, E Orlandi, A Psyrri, G Shenouda, D Sher, C Steuer, X Shan Sun, Y Tao, D Thomson, MH Tsai, N Vulquin, P Gorphe, H Mehanna, SS Yom, J Bourhis, J Thariat	05/10/2021
TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS Oral Oncology	MR Patel, L Ottenstein, M Ryan, A Farrell, M Studer, HM Baddour, K Magliocca, C Griffith, W Stokes, J Switchenko, A Aiken, M El-Deiry, CA Solares, C Steuer, N Saba, J Beitler	04/19/2021
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study Cancers	CH Chung, M Bonomi, CE Steuer, J Li, P Bhateja, M Johnson, J Masannat, F Song, JC Hernandez-Prera, BM Wenig, H Molina, JM Farinhas, CP McMullen, JT Wadsworth, KB Patel, JA Kish, J Muzaffar, K Kirtane, JW Rocco, MJ Schell, NF Saba	03/09/2021
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial Journal of Thoracic Oncology	CE Steuer, OA Jegede, SE Dahlberg, HA Wakelee, SM Keller, WJ Tester, DR Gandara, SL Graziano, AA Adjei, CA Butts, SS Ramalingam, JH Schiller	02/01/2021
Socioeconomic Factors Influence the Impact of Tumor HPV Status on Outcome of Patients With Oropharyngeal Squamous Cell Carcinoma JCO Oncology Practice	JA Marks, JM Switchenko, CE Steuer, M Ryan, MR Patel, MW McDonald, K Higgins, JJ Beitler, DM Shin, TW Gillespie, NF Saba	01/12/2021
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study Journal for ImmunoTherapy of Cancer	S Pakkala, K Higgins, Z Chen, G Sica, C Steuer, C Zhang, G Zhang, S Wang, MS Hossain, B Nazha, T Beardslee, FR Khuri, W Curran, S Lonial, EK Waller, S Ramalingam, TK Owonikoko	12/01/2020
Combinatorial approaches targeting the EGFR family and c-Met in SCCHN Oral Oncology	D Wang, Y Lu, S Nannapaneni, CC Griffith, C Steuer, G Qian, X Wang, Z Chen, M Patel, M Patel, M El-Deiry, DM Shin, X He, ZG Chen, ZG Chen, NF Saba, ZG Chen	11/02/2020
Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population The Laryngoscope	A Tkaczuk, S Trivedi, MD Mody, CE Steuer, DM Shin, AM Klein, NF Saba	10/27/2020
EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic? Translational Lung Cancer Research	CE Steuer, SS Ramalingam	10/01/2020
Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC) PLoS ONE	NF Saba, AR Dinasarapu, KR Magliocca, B Dwivedi, S Seby, ZS Qin, M Patel, CC Griffith, X Wang, M El-Deiry, CE Steuer, J Kowalski, DM Shin, ME Zwick, ZG Chen	09/28/2020
Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck Clinical Cancer Research	DM Shin, S Nannapaneni, MR Patel, Q Shi, Y Liu, Z Chen, AY Chen, MW El-Deiry, JJ Beitler, CE Steuer, SM Roser, AM Klein, TK Owonikoko, SS Ramalingam, FR Khuri, ZG Chen, NF Saba	09/17/2020
An update on the immune landscape in lung and head and neck cancers CA A Cancer Journal for Clinicians	JW Carlisle, CE Steuer, TK Owonikoko, NF Saba	08/25/2020
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma British Journal of Cancer	RD Harvey, BC Carthon, C Lewis, MS Hossain, C Zhang, Z Chen, WB Harris, OB Alese, W Shaib, MA Bilen, DH Lawson, C Wu, CE Steuer, BF El-Rayes, FR Khuri, S Lonial, EK Waller, SS Ramalingam, TK Owonikoko	07/23/2020
Surgical Resection is Justifiable for Oral T4b Squamous Cell Cancers With Masticator Space Invasion The Laryngoscope	HM Baddour, MC Ochsner, MR Patel, JM Switchenko, JJ Beitler, K Magliocca, KL Baugnon, CA Solares, CE Steuer, MW El-Deiry	05/27/2020
Outcomes and Predictive Value of Post‐adjuvant Therapy PET/CT for Locally Advanced Oral Squamous Cell Carcinoma The Laryngoscope	DC Qian, KR Magliocca, AH Aiken, KL Baugnon, DC Brandon, WA Stokes, MW McDonald, MR Patel, HM Baddour, AS Kaka, CE Steuer, NF Saba, DM Shin, JJ Beitler	02/14/2020
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors Clinical Cancer Research	TK Owonikoko, RD Harvey, B Carthon, Z Chen, C Lewis, H Collins, C Zhang, DH Lawson, OB Alese, MA Bilen, GL Sica, CE Steuer, WL Shaib, WL Shaib, C Wu, WB Harris, WB Harris, M Akce, RR Kudchagkar, RR Kudchagkar, BF El-Rayes, S Lonial, SS Ramalingam, FR Khuri, FR Khuri	01/31/2020
Demographic and Socioeconomic Factors Associated With Metastases at Presentation in HPV–Related Squamous Cell Carcinoma of the Head and Neck: An NCDB Analysis JCO Oncology Practice	MB Bean, JM Switchenko, CE Steuer, M Patel, K Higgins, M McDonald, GZ Chen, JJ Beitler, DM Shin, T Gillespie, NF Saba	01/27/2020
Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis International Journal of Radiation OncologyBiologyPhysics	S Tian, JM Switchenko, ZS Buchwald, PR Patel, JW Shelton, SE Kahn, RN Pillai, CE Steuer, TK Owonikoko, M Behera, WJ Curran, KA Higgins	01/24/2020
Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis The Oncologist	M Behera, CE Steuer, Y Liu, F Fernandez, C Fu, KA Higgins, TW Gillespie, S Pakkala, RN Pillai, S Force, CP Belani, FR Khuri, WJ Curran, SS Ramalingam	01/14/2020
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials The Lancet Oncology	RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, CM Blakely, T Seto, BC Cho, D Tosi, B Besse, SP Chawla, L Bazhenova, JC Krauss, YK Chae, M Barve, I Garrido-Laguna, SV Liu, P Conkling, T John, M Fakih, D Sigal, HH Loong, GL Buchschacher, P Garrido, J Nieva, C Steuer, TR Overbeck, DW Bowles, E Fox, T Riehl, E Chow-Maneval, B Simmons, N Cui, A Johnson, S Eng, TR Wilson, GD Demetri	12/11/2019
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy The Oncologist	MA Bilen, DJ Martini, Y Liu, JM Shabto, JT Brown, M Williams, AI Khan, A Speak, C Lewis, H Collins, HT Kissick, BC Carthon, M Akce, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master	12/05/2019
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials Cancer	DJ Martini, MR Kline, Y Liu, JM Shabto, MA Williams, AI Khan, C Lewis, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master, MA Bilen	10/24/2019
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy BMC Cancer	MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis, H Collins, M Akce, H Kissick, BC Carthon, WL Shaib, OB Alese, CE Steuer, C Wu, DH Lawson, R Kudchadkar, VA Master, B El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey	08/29/2019
Small Cell and Squamous Cell Carcinomas of the Head and Neck: Comparing Incidence and Survival Trends Based on Surveillance, Epidemiology, and End Results (SEER) Data The Oncologist	MB Bean, Y Liu, R Jiang, CE Steuer, M Patel, MW McDonald, KA Higgins, JJ Beitler, DM Shin, NF Saba	08/07/2019
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial The Lancet Oncology	D Adkins, J Ley, P Neupane, F Worden, AG Sacco, K Palka, JE Grilley-Olson, R Maggiore, NN Salama, K Trinkaus, BA Van Tine, CE Steuer, NF Saba, P Oppelt	07/24/2019
Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database Clinical Lung Cancer	S Tian, X Zhang, R Jiang, RN Pillai, TK Owonikoko, CE Steuer, NF Saba, S Pakkala, PR Patel, CP Belani, FR Khuri, WJ Curran, SS Ramalingam, M Behera, KA Higgins	06/18/2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis Lung Cancer	MM Awad, GC Leonardi, S Kravets, SE Dahlberg, A Drilon, SA Noonan, DR Camidge, SI Ou, DB Costa, SM Gadgeel, CE Steuer, PM Forde, VW Zhu, Y Fukuda, JW Clark, PA Jänne, T Mok, LM Sholl, RS Heist	05/11/2019
Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis Head & Neck	A Mohamed, B Twardy, MA Zordok, K Ashraf, A Alkhoder, K Schrapp, C Steuer, Z Chen, S Pakkala, R Pillai, J Trad Wadsworth, K Higgins, JJ Beitler, SS Ramalingam, TK Owonikoko, FR Khuri, DM Shin, M Behera, NF Saba	03/05/2019
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials Investigational New Drugs	DJ Martini, Y Liu, JM Shabto, C Lewis, MR Kline, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, VA Master, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, MA Bilen	02/06/2019
Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx Cancer	JJ Beitler, JM Switchenko, JJ Dignam, MW McDonald, NF Saba, DM Shin, KR Magliocca, RJ Cassidy, MW El-Deiry, MR Patel, CE Steuer, C Xiao, PA Hudgins, AH Aiken, WJ Curran, QT Le	12/11/2018
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy Cancer	MA Bilen, DJ Martini, Y Liu, C Lewis, HH Collins, JM Shabto, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, VA Master, SS Ramalingam, TK Owonikoko, RD Harvey	10/17/2018
Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas The Laryngoscope	RJ Cassidy, JM Switchenko, MW El-Deiry, RH Belcher, J Zhong, CE Steuer, NF Saba, MW McDonald, DS Yu, TW Gillespie, JJ Beitler	09/08/2018
Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy Cancer	RH Press, C Zhang, RJ Cassidy, MJ Ferris, J Zhong, CE Steuer, RN Pillai, TK Owonikoko, S Kahn, SS Ramalingam, PR Patel, WJ Curran, HG Shu, GL Sica, KA Higgins	08/18/2018
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation Cancer Cell	L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang, HB Kang, L Song, D Wang, G Zhang, J Fan, TJ Boggon, L Zhou, J Kowalski, CK Qu, CE Steuer, GZ Chen, NF Saba, LH Boise, TK Owonikoko, FR Khuri, KR Magliocca, DM Shin, S Lonial, S Kang	07/20/2018
A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma Molecular Cancer Therapeutics	CE Steuer, CC Griffith, S Nannapaneni, MR Patel, Y Liu, KR Magliocca, MW El-Deiry, C Cohen, TK Owonikoko, DM Shin, ZG Chen, NF Saba	02/13/2018
Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? Journal of Clinical Oncology	CE Steuer, SS Ramalingam	01/16/2018
Health care disparities among octogenarians and nonagenarians with stage III lung cancer Cancer	RJ Cassidy, X Zhang, JM Switchenko, PR Patel, JW Shelton, S Tian, RH Nanda, CE Steuer, RN Pillai, TK Owonikoko, SS Ramalingam, FG Fernandez, SD Force, TW Gillespie, WJ Curran, KA Higgins	01/08/2018
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients Annals of Oncology	J Remon, CE Steuer, SS Ramalingam, E Felip	01/01/2018
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non–Small Cell Lung Cancer: A Phase I Study Journal of Thoracic Oncology	KA Higgins, RN Pillai, Z Chen, S Tian, C Zhang, P Patel, S Pakkala, J Shelton, SD Force, FG Fernandez, CE Steuer, TK Owonikoko, SS Ramalingam, JD Bradley, WJ Curran	09/13/2017
Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy Radiotherapy and Oncology	MJ Ferris, J Zhong, JM Switchenko, KA Higgins, RJ Cassidy, MW McDonald, BR Eaton, KR Patel, CE Steuer, HM Baddour, AH Miller, DW Bruner, C Xiao, JJ Beitler	08/18/2017
Health care disparities among octogenarians and nonagenarians with stage II and III rectal cancer Cancer	RJ Cassidy, JM Switchenko, E Cheng, R Jiang, J Jhaveri, KR Patel, DG Tanenbaum, MC Russell, CE Steuer, TW Gillespie, MW McDonald, JC Landry	07/31/2017
Next‐generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy Cancer	RJ Cassidy, X Zhang, PR Patel, JW Shelton, CE Escott, GL Sica, MR Rossi, CE Hill, CE Steuer, RN Pillai, SS Ramalingam, TK Owonikoko, M Behera, SD Force, FG Fernandez, WJ Curran, KA Higgins	06/13/2017
Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base Cancer	KB Naik, Y Liu, M Goodman, TW Gillespie, A Pickens, SD Force, CE Steuer, TK Owonikoko, SS Ramalingam, K Higgins, JJ Beitler, DM Shin, FF Willingham, B El-Rayes, JC Landry, FG Fernandez, NF Saba	05/02/2017
Guideline-concordant Care Improves Overall Survival for Locally Advanced Non–Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis Clinical Lung Cancer	HZ Ahmed, Y Liu, K O'Connell, MZ Ahmed, RJ Cassidy, TW Gillespie, P Patel, RN Pillai, M Behera, CE Steuer, TK Owonikoko, SS Ramalingam, WJ Curran, KA Higgins	04/28/2017
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer JNCI Journal of the National Cancer Institute	DA Goldstein, N Gordon, M Davidescu, M Leshno, CE Steuer, N Patel, SM Stemmer, A Zer	03/16/2017
Development of Late Toxicities in Patients with Oral Tongue Cancer Treated with Surgical Resection and Adjuvant Radiation Therapy Frontiers in Oncology	M Sayan, RJ Cassidy, JM Switchenko, OA Kayode, NF Saba, CE Steuer, DM Shin, JT Wadsworth, M El-Deiry, M Patel, JJ Beitler, KA Higgins	01/10/2017
Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor Oncology	M Evans, Y Liu, C Chen, C Steuer, R Cassidy, J Landry, K Higgins, JJ Beitler, F Willingham, TK Owonikoko, SS Ramalingam, DM Shin, NK Jegadeesh, B El-Rayes, F Fernandez, AM Krasinskas, T Gillespie, NF Saba	01/01/2017
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non–Small-Cell Lung Cancer JAMA Oncology	CE Steuer, M Behera, V Ernani, KA Higgins, NF Saba, DM Shin, S Pakkala, RN Pillai, TK Owonikoko, WJ Curran, CP Belani, FR Khuri, SS Ramalingam	12/19/2016
Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base Clinical Lung Cancer	CE Steuer, M Behera, Y Liu, C Fu, TW Gillespie, NF Saba, DM Shin, RN Pillai, S Pakkala, TK Owonikoko, FR Khuri, SS Ramalingam	12/07/2016
An update on larynx cancer CA A Cancer Journal for Clinicians	CE Steuer, M El-Deiry, JR Parks, KA Higgins, NF Saba	11/29/2016
Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base Cancer	RJ Cassidy, Y Liu, K Patel, J Zhong, CE Steuer, DA Kooby, MC Russell, TW Gillespie, JC Landry	10/25/2016
The End of Nihilism: Systemic Therapy of Advanced Non–Small Cell Lung Cancer Annual Review of Medicine	V Ernani, CE Steuer, M Jahanzeb	09/13/2016

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.8	One star One star One star One star One half star	Provider showed concern
4.8	One star One star One star One star One half star	Provider explained things clearly
4.8	One star One star One star One star One half star	Provider discussed treatment options
4.8	One star One star One star One star One half star	Provider included you in decisions
4.7	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	03/13/2026	The Doctor was amazing he laid out a clear path going forward he was personable, friendly, answered questions he really just made me feel like I was in good hands with a doctor that was confident and had clear direction. A really nice guy!!!
One star One star One star One star One star	02/24/2026	Dr. Steuer was exceptionally perceptive about my concerns and provided me options about tracking and observing progression of cancer. He also informed me of potential treatment options for future consideration and provided me with a printout of one, which was delivered and discussed by the pharmacist. I appreciate receiving this information in advance, empowering me to participate in decisions affecting my wellness.
One star One star One star One star One star	02/20/2026	The Doctor did great.
One star One star One star One star One star	02/10/2026	I was afraid I would have a Dr that rushed through this very important appointment. This was not the case at all! Dr Steur spent nearly an hour explaining and most importantly, listening to our concerns and answering our questions. I am so happy he is over my care. You couldn't ask for anything better than a doctor who sees and you.
One star One star One star One star One star	02/06/2026	Dr. Steuer is absolutely the best!
One star One star One star One star One star	01/06/2026	The best
One star One star One star One star One star	12/09/2025	Dr. Steuer is wonderful. So is his PA Courtney who we have seen multiple times but not for this visit. Dr. Steuer is kind, intelligent, up to date on current evidence, trials and standard of care. He individualized our treatment plan taking into account preferences and health status. He has been very supportive throughout this arduous journey and we are so grateful for him and all of our Emory team.
One star One star One star One star One star	12/07/2025	Dr. Steuer was very positive, reassuring and hopeful. He listened to all of our concerns, answered our questions and provided helpful suggestions.
One star One star One star One star One star	10/07/2025	Exceptional visit with both listening and also explanations
One star One star One star One star One star	07/19/2025	Again it was just very comfortable meeting. I felt like he explained everything well and used language that made me understand. In Oncology that isn't always easy to do.
One star One star One star One star One star	07/15/2025	Great communication.
One star One star One star One star One star	06/25/2025	I tell everyone how great Emory is!!! My doctors, surgeons, and their associated staffs are tops!!!
One star One star One star One star One star	05/24/2025	I hoe none of my family or friends needs this type of doctor but if they did I'd recommend him
One star One star One star One star One star	05/23/2025	If I could rate these areas a 10, I would.
One star One star One star One star One star	05/14/2025	Truly excellent
One star One star One star One star One star	05/02/2025	Dr Steuer is always ahead on the latest cancer treatments. Fortunate to have him on my team!
One star One star One star One star One star	03/20/2025	Very professional, respectful of my wishes. Well-educated and concerned for my well-being. I visited two other cancer centers and ultimately chose Emory due to the confidence in and comfort felt with Dr. Steuer. He listened and prioritized my needs over his own agenda.
One star One star One star One star One star	01/19/2025	Dr. Steuer is the best!
One star One star One star One star One star	01/17/2025	First appointment with this doctor. Felt very at ease and he showed interest ion my questions, etc. I was so very pleased.
One star One star One star One star One star	01/11/2025	Dr Steuer is very professional and knowledgeable. He is great Dr to take care of patients
One star One star One star One star One star	12/06/2024	Very Good
One star One star One star One star One star	11/06/2024	Listened carefullly and provided guidance on what the next step should be.
One star One star One star One star One star	10/27/2024	Feel like Dr Steuer is genuinely interested and open to all possible protocols to beat cancer. He is very accessible and shows true care for my quality of life.
One star One star One star One star One star	10/26/2024	Dr. Steuer Is absolutely the best and his staff are outstanding!
One star One star One star One star One star	10/16/2024	Everybody that talked to me.Seemed to be on the same page and knew what the situation was.I'm very pleased
One star One star One star One star One star	09/18/2024	Excellent
One star One star One star One star One star	07/23/2024	Dr Steuer provided the options I have, fully explaining them. Answered all questions asked and addressed our concerns.
One star One star One star One star One star	07/22/2024	Always tell people to use my Dr